Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Deferred Revenue (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of Current Deferred Revenue data on record, last reported at $954000.0 in Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 854.0% year-over-year to $954000.0; the TTM value through Sep 2025 reached $954000.0, up 854.0%, while the annual FY2024 figure was $479000.0, N/A changed from the prior year.
  • Current Deferred Revenue reached $954000.0 in Q3 2025 per DNTH's latest filing, up from $479000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $954000.0 in Q3 2025 and bottomed at $100000.0 in Q4 2022.
  • Average Current Deferred Revenue over 4 years is $321222.2, with a median of $100000.0 recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: changed 0.0% in 2024, then surged 854.0% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then surged by 379.0% to $479000.0 in 2024, then soared by 99.16% to $954000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $954000.0 in Q3 2025, $479000.0 in Q2 2025, and $479000.0 in Q1 2025.